Inactive Instrument

Actelion Ltd Share Price Swiss Exchange

Stocks

End-of-day quote Swiss Exchange
- ^CHF	-

31/17/31	Actelion : France's Sanofi raises earnings forecast, pleased with eczema drug uptake	RE
19/17/19	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE

31/17/31	Actelion : France's Sanofi raises earnings forecast, pleased with eczema drug uptake	RE
19/17/19	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
19/17/19	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
09/17/09	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
09/17/09	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
09/17/09	Actelion : Johnson & Johnson expects to complete of Actelion offer on June 16	RE
22/17/22	Akzo Nobel : Cross-border M&A between U.S. and European firms at 10 year high	RE
18/17/18	Actelion : Johnson & Johnson offers EU concessions over Actelion deal	RE
20/17/20	Actelion : Johnson & Johnson target Actelion could exit Swiss benchmark SMI index this month	RE
18/17/18	Actelion : Johnson & Johnson first quarter revenue misses estimates; new forecast includes Actelion	RE
05/17/05	Actelion : shareholders back R&D spinoff, keep J&J deal on track	RE
31/17/31	Actelion : J&J declares Actelion tender offer a success, sees closing in second quarter	RE
23/17/23	Genmab A/S : and J&J's cancer drug set for blockbuster sales this year	RE

06/20/06	Actelion : Pharmaceuticals US, Inc, - Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents	AQ
31/17/31	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	GL
30/17/30	Actelion : Befreiung von Publizitätspflichten zur Aufrechterhaltung der Kotierung	GL
16/17/16	Actelion : Johnson & Johnson Completes Acquisition of Actelion	GL
16/17/16	Actelion : Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange	PU

29/18/29	Après Bioverativ, Sanofi s'empare de la biotech belge Ablynx pour 3,9 mrd EUR
29/18/29	Après Bioverativ, Sanofi rachète la biotech belge Ablynx pour 3,9 mrd EUR
22/18/22	Avec Bioverativ, Sanofi devient un leader mondial dans l'hémophilie
31/17/31	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017
30/17/30	Actelion: la décotation est agendée au 7 novembre

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	-2.11%	-1.68%	+44.52%	+95.15%	6.69TCr
ARGENX SE	-0.23%	-4.45%	+30.39%	+73.64%	6.2TCr
INSMED INCORPORATED	+1.67%	+2.47%	-11.23%	+388.34%	2.83TCr
WUXI BIOLOGICS (CAYMAN) INC.	-1.05%	-4.43%	+30.56%	+10.07%	2.46TCr
BIONTECH SE	+0.34%	-6.78%	-7.27%	-17.99%	2.43TCr
GENMAB A/S	+0.43%	-3.37%	+14.85%	-19.29%	1.94TCr
PHARMAESSENTIA CORPORATION	-3.03%	-2.29%	+185.12%	+334.07%	1.68TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.94%	-4.94%	-5.29%	+495.65%	1.42TCr
EXELIXIS, INC.	-2.28%	-4.90%	+43.64%	+155.21%	1.39TCr
Average	-0.91%	-3.46%	+36.14%	+168.32%	3TCr
Weighted average by Cap.	-0.84%	-3.06%	+33.46%	+133.67%